Discovery of serum protein biomarkers for prostate cancer progression by proteomic analysis.

Abstract

SELDI-TOF-MS technology has facilitated the discovery of prognostic biomarkers in serum that can successfully discriminate aggressive from indolent PCa and also differentiate between recurrence groups.